Truveta (@truveta) header
Truveta (@truveta) profile picture

Truveta delivers the most complete, timely, and clean regulatory-grade EHR data for scientifically rigorous research. Our mission is Saving Lives with Data.

Seattle area, Washington
Joined October 2017
Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)Photo by Truveta (@truveta)
When a major trial showed that aspirin could be safely omitted for HeartMate 3 patients on warfarin, how quickly did practice change, and did real-world outcomes hold up? 💡 A new study in the Journal of Cardiac Failure used Truveta Data to find out. Researchers tracked aspirin use across 3,365 adults with an LVAD and found it fell from 90.2% in 2023 to 52.7% in 2025, though it persisted most often in patients with vascular disease. Avoiding aspirin was not associated with a higher adjusted risk of death or major complications. To build confidence in the findings, the team benchmarked real-world event definitions against a national registry of nearly 9,000 patients, showing how EHR data can support early safety monitoring after a trial-driven change in care. 🔗 Learn more: tr.vet/4iXuZu6
12
After a Whipple procedure, patients often go home with daily blood-thinner injections. Because patients often struggle to self-inject or have to rely on others to help, researchers at St. Peter's Health Partners wondered if there was a way to reduce the burden on patients. With no existing literature on oral blood thinners used for patients recovering from a Whipple procedure and funding hard to secure, they turned to data on patients treated within their own health system. The challenge was that local analysis included just 57 patients. Using Truveta Data, they expanded the study to nearly 900 patients across several member health systems throughout the US, comparing the standard injectable enoxaparin with the oral apixaban. See how a question from everyday patient care became a real-world evidence study: tr.vet/4kfVn4J
33
💊 When a new drug comes to market, often little evidence exists about its safety in pregnancy. For important reasons, pregnant women are excluded from nearly all clinical trials that are used to establish drug efficacy. To fill this knowledge gap, Truveta Data has enabled researchers with linked mother-child data covering +1M mothers and their children, with +4.5M pregnancies and +300K added each year. Hear from SVP of Evidence Services John Seeger, PharmD, DrPH, FISPE on how Truveta makes pregnancy safety research possible: tr.vet/4iXJHBu
1
60
Real-world data is changing how medical affairs teams understand care after approval 📈 Approval, publication, and guideline updates don’t automatically translate into consistent patient care. Medical affairs leaders need a clearer view of what happens next and how clinical factors shape those decisions. Join our webinar on December 8 for an exclusive conversation with Ryan Ahern, MD, MPH and Johnathan Lancaster, MD, PhD about the future of medical affairs. Register here: tr.vet/4C0WFHb
44
Following our research presentation at #AMIA2026, SVP of Engineering Sujatha Sagiraju shares a behind-the-scenes look at how the Truveta team normalized 2.5 million cancer staging records. Learn about the challenges, including gaps in existing standards and a long tail of values that can’t all be mapped at once, and what’s next: tr.vet/48NKujx @AMIAinformatics
63
Thank you #ISPOREurope! 🇦🇹 Our team had an amazing time in Vienna connecting with the HEOR community. It was great to talk with so many of you about how real-world data can inform evidence generation, market access, and decisions about patient care. 👋 See you next year! @ISPORorg
1
50
📣 Yesterday at #AMIA2026 in Dallas: Clinical Terminologist Jamalynne Deckard, MS shared insights on the syntactic and semantic normalization of more than 2.5M cancer staging records. Thank you Jami for representing Truveta at @AMIAinformatics! Read the research: tr.vet/3UFMHu8
1
69
The past couple of days at #ISPOREurope have been full of learnings: Partner-Facing Research Analyst Claire Campbell, PhD shared our findings across four poster presentations: 🔗 Depression severity change following GLP-1 vs non-GLP-1: tr.vet/4zD9s0L 🔗 Profiles among adults with obesity treated with GLP-1 vs non-GLP-1: tr.vet/4zDmg7r 🔗 Food insecurity and hypertensive medication adherence: tr.vet/4eXL6qg 🔗 Antihypertensive prescribing patterns and blood pressure control: tr.vet/3WBnFgd @ISPORorg
62
Today at #ISPOREurope, interim-co CEO, Chief Medical Officer, and co-founder Ryan Ahern, MD, MPH took the stage to share how we help teams understand what happens after a new drug, device, or guideline launches. Truveta's care insights solution gives a real-time look at how treatments are used in clinical practice. It draws on daily updated, de-identified EHR data and clinical notes that capture the context behind decisions, like side effects and access barriers. Thank you to everyone who joined the session and to the ISPOR community for the great conversations. Be sure to stop by our booth (#1222) and say hello 👋 Learn more: tr.vet/3WBfXTg @ISPORorg
1
76
Introducing Truveta care insights: a real-time look at how treatments are used in clinical practice. Once a new drug, device, or guideline reaches the real world, the most important questions begin. Who is starting therapy? Are prescriptions being filled? Why do patients stop or switch? How quickly does practice change when new evidence emerges? Care insights draws on daily-updated, de-identified EHR data along with clinical notes that capture the context behind decisions, like side effects and access barriers. With Truveta Intelligence, teams can ask questions in natural language and see emerging patterns in a matter of days, rather than months later. Read the full announcement: tr.vet/3WBfXTg
38
💡 GLP-1s now account for more than 8% prescriptions in the US. The latest GLP-1 monitoring report, updated through September 2026, shows how quickly the landscape is moving: 📈 Anti-obesity prescribing increased right after the launch of Medicare GLP-1 Bridge program 💉 Tirzepatide prescribing grew 11% in three months and remains the most prescribed GLP-1 medication 💊 Orforglipron (Foundayo pill) prescribing more than doubled after its April approval Dive into the analysis: tr.vet/4sMs0Jp
41
📍 Heading to #AMIA2026 in Dallas? Join Clinical Terminologist Jamalynne Deckard, MS on Monday, November 9 as she shares insights on the syntactic and semantic normalization of more than 2.5M cancer staging records. Researchers used our LLM, TLM-Oncology, to extract staging data from clinical notes across all solid tumors, then normalized it to SNOMED CT in the Truveta Data Model. The result is a consistent, research-ready dataset for health system, academic, government, and life science researchers. We hope to see you at @AMIAinformatics!
1
58
New research from #EASD2026: Adults with type 2 diabetes on basal insulin who used CGM had a 45% lower mortality risk at one year and 36% lower at two years, plus lower risk of heart attack, stroke, and hospitalization. Using target trial emulation, the analysis of 28,000 patients within Truveta Data adds to the evidence that the value of CGMs may extend well beyond glucose control. Swipe through for the highlights, and dive into the findings: tr.vet/4kvnyfZ
35
Since its launch on July 1, the Medicare GLP-1 Bridge program expanded access to GLP-1 medications for seniors by reducing out-of-pocket costs. Three months later, new findings from Truveta Research show GLP-1 prescribing among adults aged 65+ remains elevated: ➡️ GLP-1 prescribing was 20.6% higher in September compared to June ➡️ First-time GLP-1 prescriptions was up 21.3% ➡️ Tirzepatide (Zepbound) prescribing rose 71.1% and semaglutide (Wegovy) prescribing rose 32.8% Read the full analysis: tr.vet/48wOJ2M
1
65
Rare diseases have historically been difficult to study in real-world care, and new research using Truveta Data is helping change that 🔎 A study published in the Orphanet Journal of Rare Diseases characterized 214 patients with ornithine transcarbamylase deficiency (OTCD), a rare genetic disorder. Researchers combined longitudinal EHR data with symptoms and clinical details extracted from physician notes not captured in structured data to create a more complete view and advance care for this rare patient population. Read the research: tr.vet/4zjtM7n
1
1
73
Nothing spooky about these new Truvetans 🎃 Welcome to the team! We couldn't be more grateful to have you on the team 💙
45
📣 Live from IMPACCT RWE in Boston: VP of Partnerships Conor Wyand shared how Truveta is shortening the time to insight, giving researchers a faster way to spot emerging trends, explore new questions, and turn what they learn into trusted evidence. It’s a new way of approaching real-world research: learn faster, ask better questions, and ultimately generate evidence that can improve healthcare.
38
Our IDC team in Hyderabad continues to grow! Join us in giving them a warm welcome 👏
37
📣 Today at AMCP Nexus in San Diego: Director of Research Brianna Cartwright, MS shared an updated look at early uptake of oral semaglutide for obesity (Wegovy pill) using Truveta Data from more than 182,000 patients through September 2026. Dive into the findings: tr.vet/4jLp4KP #AMCPNexus @amcporg
1
1
103
🫀 When someone is hospitalized for heart failure, doctors work to remove extra fluid. But how intensive does that treatment need to be? A new study in the Journal of Cardiac Failure (@JCardFail) used Truveta Data to look at more than 109,000 heart failure hospitalizations across US health systems. They found that more intensive diuretic treatment removed more fluid, but it wasn’t linked to fewer readmissions or deaths within 90 days. Patients who lost more weight did have lower odds of those outcomes, whichever treatment they got. Read the research: tr.vet/3WcAspb
54